G Gatti

Summary

Affiliation: Vertex Pharmaceuticals
Country: USA

Publications

  1. ncbi The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children
    G Gatti
    I Department of Infectious Diseases c o G Gaslini Institute University of Genoa, Genoa, Italy
    HIV Med 3:125-8. 2002
  2. ncbi Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children
    G Gatti
    Gaslini Childrens Hospital, Genoa, Italy
    Clin Infect Dis 36:1476-82. 2003
  3. ncbi Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection
    G Gatti
    Department of Infectious Diseases, University of Genoa, Genoa, Italy
    Antimicrob Agents Chemother 44:752-5. 2000
  4. ncbi Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome
    G Gatti
    First Department of Infectious Diseases, University of Genoa, Genoa, Italy
    Br J Clin Pharmacol 48:704-11. 1999
  5. ncbi Tenofovir use in a patient with a severe renal impairment
    A Di Biagio
    Department of Infectious Diseases, San Martino Hospital, University of Genoa, Genoa, Italy
    HIV Med 5:450-1. 2004
  6. ncbi Erythromycin resistance in Streptococcus pyogenes in Italy
    M Bassetti
    Infectious Diseases Department, University of Genoa, G Gaslini Children s Hospital, Genoa, Italy
    Emerg Infect Dis 6:180-3. 2000
  7. ncbi Updated European recommendations for the clinical use of HIV drug resistance testing
    A M Vandamme
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antivir Ther 9:829-48. 2004
  8. ncbi The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis
    M Cruciani
    Department of Infectious Diseases, HIV Screening Center, Verona, Italy
    Clin Infect Dis 33:1922-30. 2001
  9. ncbi Penetration of didanosine in semen of HIV-1-infected men
    M Cruciani
    Centre of Preventive Medicine and HIV Outpatient Clinic, Via Germania 20, 37135 Verona, Italy
    J Antimicrob Chemother 57:1244-7. 2006

Detail Information

Publications9

  1. ncbi The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children
    G Gatti
    I Department of Infectious Diseases c o G Gaslini Institute University of Genoa, Genoa, Italy
    HIV Med 3:125-8. 2002
    ..We studied a number of factors, including ritonavir plasma levels, and their capability of predicting response to therapy with ritonavir (RTV)...
  2. ncbi Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children
    G Gatti
    Gaslini Childrens Hospital, Genoa, Italy
    Clin Infect Dis 36:1476-82. 2003
    ..The variability of trough concentrations was extremely high, particularly among recipients of the twice-daily regimen, resulting in a higher number of patients with subinhibitory concentrations of nelfinavir in this group...
  3. ncbi Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection
    G Gatti
    Department of Infectious Diseases, University of Genoa, Genoa, Italy
    Antimicrob Agents Chemother 44:752-5. 2000
    ..Due to the low number of patients enrolled in this study, our results should be confirmed by a larger study...
  4. ncbi Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome
    G Gatti
    First Department of Infectious Diseases, University of Genoa, Genoa, Italy
    Br J Clin Pharmacol 48:704-11. 1999
    ..The purpose of the study was to compare the pharmacokinetic parameters of rifabutin obtained in a group of patients without wasting syndrome (NWS) with those obtained in a group with wasting syndrome (WS)...
  5. ncbi Tenofovir use in a patient with a severe renal impairment
    A Di Biagio
    Department of Infectious Diseases, San Martino Hospital, University of Genoa, Genoa, Italy
    HIV Med 5:450-1. 2004
  6. ncbi Erythromycin resistance in Streptococcus pyogenes in Italy
    M Bassetti
    Infectious Diseases Department, University of Genoa, G Gaslini Children s Hospital, Genoa, Italy
    Emerg Infect Dis 6:180-3. 2000
    ..pyogenes treated with clarithromycin and in 22 (88%) of 25 patients with erythromycin-susceptible strains. The constitutive-resistant phenotype was correlated with failure of macrolide treatment...
  7. ncbi Updated European recommendations for the clinical use of HIV drug resistance testing
    A M Vandamme
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antivir Ther 9:829-48. 2004
    ..The panel also encourages the timely collection of epidemiological information to estimate the impact of transmission of resistant HIV and the prevalence of HIV-1 non-B subtypes in the different European countries...
  8. ncbi The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis
    M Cruciani
    Department of Infectious Diseases, HIV Screening Center, Verona, Italy
    Clin Infect Dis 33:1922-30. 2001
    ..78-1.56) were similar regardless of HIV-1 positivity of index cases. These data suggest that tuberculosis patients with HIV-1 infection are not intrinsically more infectious to their contacts than are HIV-1-negative tuberculosis patients...
  9. ncbi Penetration of didanosine in semen of HIV-1-infected men
    M Cruciani
    Centre of Preventive Medicine and HIV Outpatient Clinic, Via Germania 20, 37135 Verona, Italy
    J Antimicrob Chemother 57:1244-7. 2006
    ..We have investigated didanosine penetration in seminal plasma of 16 HIV-infected patients...